Focused on the
discovery, design,
& development
SCROLLof innovative
peptide-based
medicines
SCROLLfor people
who need them
SCROLL-
Share price information
ZEAL (COP)
794.50DKKZealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL.
More Stock information -
Annual report 2023
-
Corporate presentation
Latest news
View all news-
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
READ MORE -
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
READ MORE -
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
READ MORE -
Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
READ MORE
Innovating across a range of disease areas
Obesity
As one of the greatest healthcare challenges of our time, obesity and overweight are associated with more than 220 complications and co-morbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation. Zealand Pharma is working to address this chronic disease with differentiated product candidates.
Read moreRare diseases
Severely impacting quality of life, many rare diseases represent major unmet needs. Zealand Pharma has a long-standing commitment to people living with congenital hyperinsulinism (CHI) and short bowel syndrome (SBS).
Congenital hyperinsulinism Short Bowel SyndromeChronic inflammation
Through damage to tissues and organs, chronic inflammation can lead to the development of a broad range of potentially disabling or life-threatening illnesses. Zealand Pharma believes peptide medicines present opportunities for innovation in the treatment of chronic inflammatory diseases.
Read moreType 1 diabetes
Despite advances in insulin chemistry and delivery systems, achieving tight control over blood-glucose levels remains a daily challenge for those living with type 1 diabetes, increasing the risk of diabetes complications. Zealand Pharma aspires to improve type 1 diabetes management.
Read moreAn innovative R&D pipeline
Safety, tolerability, and clinical effects of ZP8396, an amylin analog
Featured publication
Results from a 6-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in October 2024.
Fostering an enriching workplace
At Zealand, we promote engagement, growth, diversity and inclusion. We believe that engaged and motivated employees with a passion for making a difference bring a positive mindset and inspiring level of energy to work. Our highly skilled employees are at the center of the medical treatment options that we design and develop for patients. We pride ourselves on our ability to work together as one team and to foster a strong and engaging company culture founded on collaboration, courage, empowerment, and trust.
Would you like to stay up to date with Zealand news?
Join our email list to receive company announcements and press releases directly to your inbox.